✦ LIBER ✦

Safety profile of histamine dihydrochloride administered with interleukin-2 in patients with advanced metastatic malignant melanoma

✍ Scribed by S.J. O'Day; J. Glaspy; E. Whitman; C.L. Kass; K.R. Gehlsen; S.S. Agarwala

Book ID: 117658146
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 180 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)80777-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Histamine dihydrochloride administered w

Histamine dihydrochloride administered with interleukin-2 increases survival duration in patients with ocular melanoma with liver metastases

✍ S. Agarwala; A. Hauschild; J. Glaspy; K.R. Gehlsen; P. Naredj; S. O'Day 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 186 KB

The health-related quality-of-life impac

✍ Kathleen M. Beusterien, Stacey J. Ackerman, Kathryn Plante, John Glaspy, Peter N 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 166 KB

Evaluation of interleukin-2 administered

Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma

✍ Sewa S. Legha; Mary Ann Gianan; Carl Plager; Omar E. Eton; Nicholas E. J. Papado 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 726 KB

## BACKGROUND. Interleukin-2 (IL-2) has been used widely in the treatment of advanced melanoma, most often using a high dose bolus schedule of administration. We have evaluated the antitumor activity and toxicity of IL-2 when administered by a continuous infusion schedule in patients with metastat

A phase II study of dacarbazine and cisp

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

✍ Lawrence E. Flaherty; Bruce G. Redman; Silvana Martino; Michael Kraut; Manuel Va 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 588 KB

Phase II study of subcutaneously adminis

Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma

✍ Bellet, Robert E. ;Catalano, R. B. ;Mastrangelo, Michael J. ;Berd, David 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

## Abstract Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC‐45388) and a nitrosourea were treated with 5‐azacytidine (NSC‐102816). 5‐Azacytidine was administered subcutaneously at a dosage of 100 mg/m^2^/day for 10 days. Twenty‐six (26) patients were evaluab

Phase I trial of subcutaneous recombinan

Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma

✍ Omar Eton; Michael G. Rosenblum; Sewa S. Legha; Wehei Zhang; Mary Jo East; Agop 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 3 views

## Abstract ## BACKGROUND Interleukin‐2 (IL‐2) has activity in metastatic melanoma when given in high doses by the intravenous (IV) route, but its side effects and effectiveness when given in intermediate to high doses by the subcutaneous (SC) route have not been studied adequately. This study sou